Equity Research Diagnostics & Research

Should You Buy ProPhase Labs, Inc. Stock in 2026?

By CirclFi Research Team · · Updated · 0/13 models active

According to the CirclFi Deep Alpha Valuation Engine, ProPhase Labs, Inc. (PRPH) scores 4.7/10 on our Quality of Company framework, indicating mixed operational fundamentals. At the current price of $0.01, our multi-model valuation analyzes whether the market has already discounted these weaknesses.

The short answer: 0 of 0 CirclFi valuation models project upside for ProPhase Labs, Inc. (PRPH) at $0.01 — the models are evenly split, with a Quality Score of 4.7/10 and Value-Trap risk of 41/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.

Key Takeaways

  • Models are split: 0 bullish vs 0 bearish
  • Quality Score: 4.7/10 — Weak — below-average fundamentals
  • Value Trap Risk: 41/100 — Elevated — exercise caution
  • Fair Value Range: — – —

Bullish Models

0 / 0

Bearish Models

0 / 0

Quality Score

4.7 /10

Weak — below-average fundamentals

Value Trap Risk

41 /100
Elevated

Elevated — exercise caution

Model Consensus

0 /13
Active Models

Full institutional coverage

What Is the Investment Case for ProPhase Labs, Inc. (PRPH) in 2026?

What Is the Bull Case vs the Bear Case for ProPhase Labs, Inc. (PRPH)?

Bull case versus bear case for ProPhase Labs, Inc. (PRPH) at $0.01, derived from 0 active CirclFi valuation models on 2026-10-07.
Bull case Bear case
No active model projects meaningful upside for PRPH at $0.01. Bulls would have to argue that qualitative factors the models cannot measure will unlock value. No active model flags significant downside for PRPH. The Value Trap score of 41/100 still argues for some caution.

How Does PRPH Compare to Its Diagnostics & Research Peers?

FRNM Freenome, Inc.
4.8
NSTM NovelStem Internatio
4.2
ISPC iSpecimen Inc.
4.8
NDRA ENDRA Life Sciences
4.0
BIAF bioAffinity Technolo
4.9
FUNI Hypha Labs, Inc.
3.9
MTD Mettler-Toledo Inter
8.7
CDNA CareDx, Inc.
7.3

Valuation data pages: FRNM · NSTM · ISPC · NDRA · BIAF · FUNI · MTD · CDNA · LDDD · IDXX · MEDP

Which Other Stocks Score Like PRPH on Quality?

Closest companies to PRPH’s Quality of Company score of 4.7/10, across all industries.

Why Do CirclFi’s 0 Models Disagree on PRPH?

What Are the Biggest Risks of Buying PRPH Stock?

Weak Fundamentals

QOC 4.7/10 signals below-average quality.

Value Trap Warning

VT score 41/100 — apparent discount may mask decay.

Macro/Sector Risk

Diagnostics & Research headwinds could affect earnings trajectory.

Model Limitations

Backward-looking models cannot predict disruptions.

Want the full 13-model breakdown?

See every fair value, confidence score, and value trap analysis.

View PRPH Data Page →

So Is ProPhase Labs, Inc. (PRPH) Worth Buying in 2026?

ProPhase Labs, Inc. currently lacks sufficient model coverage for a definitive valuation conclusion. We recommend monitoring as additional SEC filing data becomes available.

These are quantitative model outputs, not investment recommendations. ProPhase Labs, Inc.'s future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →

What Else Do Investors Ask About PRPH Stock?

Should I buy PRPH stock right now?

Based on CirclFi's multi-model analysis, 0 of 0 models see upside for PRPH at $0.01. No active models currently project upside, suggesting the market price may already reflect or exceed fair value. This is not a buy recommendation — see our full disclaimer.

What are the biggest risks of investing in ProPhase Labs, Inc.?

Key risks include: an elevated Value Trap score of 41/100, suggesting apparent undervaluation may mask deteriorating fundamentals; a below-average Quality Score of 4.7/10, indicating fundamental weakness; limited model coverage (0/13 active), reducing analytical confidence; general market and sector-specific risks affecting Diagnostics & Research companies. Always diversify and consult a financial advisor.

How does PRPH compare to its competitors?

Among Diagnostics & Research peers, PRPH holds a Quality Score of 4.7/10. Comparable companies include FRNM (QOC 4.8), NSTM (QOC 4.2), ISPC (QOC 4.8). The relative ranking helps investors identify whether PRPH offers better fundamental quality than alternatives in the same sector.

Is PRPH a good long-term investment?

Long-term investment potential depends on fundamental quality and sustainable competitive advantages. PRPH's Quality Score of 4.7/10 raises concerns about long-term viability without significant operational improvements. Check our full data page for all 13 model estimates.

What price should I buy PRPH at?

CirclFi does not provide target buy prices or price alerts. However, our 0 active models produce fair value estimates ranging from — to —. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.

Want the complete picture?

See all 13 model estimates, confidence scores, and the full valuation table for PRPH.

View PRPH Data Page Full Terminal — $60/mo

Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →